# EDGAR Filing Document

**Accession Number:** 0001137883
**File Stem:** 0001104659-26-064632
**Filing Date:** 2026-5
**Character Count:** 34904
**Document Hash:** 1ee7c0f912d5d5d9d5d5117137de5807
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-064632.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001104659-26-064632

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260521

**DATE AS OF CHANGE**: 20260520

**EFFECTIVENESS DATE**: 20260521

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRAINSTORM CELL THERAPEUTICS INC.
- **CENTRAL INDEX KEY:** 0001137883
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 207273918
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-296091
- **FILM NUMBER:** 261005241

**BUSINESS ADDRESS:**
- **STREET 1:** 1325 AVENUE OF AMERICAS
- **STREET 2:** 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 201-488-0460

**MAIL ADDRESS:**
- **STREET 1:** 1325 AVENUE OF AMERICAS
- **STREET 2:** 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRAINSTORM CELL THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20041122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GOLDEN HAND RESOURCES INC
- **DATE OF NAME CHANGE:** 20030827

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WIZBANG TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20010409

**As filed with the Securities and Exchange Commission on May 20, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

------

**BRAINSTORM CELL THERAPEUTICS INC.**

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **20-7273918** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**1325 Avenue of Americas, 28th Floor, New York, NY, 10019**<br> (Address of Principal Executive Offices, Zip Code)

**2014 Stock Incentive Plan**

**2014 Global Share Option Plan**

(Full title of the plan)

**Chaim Lebovits**

**President and Chief Executive Officer**

**Brainstorm Cell Therapeutics Inc.**

**1325 Avenue of Americas, 28th Floor**

**New York, NY 10019**

(Name and address of agent for service)

**(201) 488-0460**

(Telephone number, including area code, of agent for service)

------

***Copies to:***

**Faith L. Charles, Esq.**

**Thompson Hine LLP**

**300 Madison Avenue, 27th Floor**

**New York, New York 10017**

**Phone: (212) 908-3905**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (this "Registration Statement") is being filed to register an additional 5,500,000 shares of common stock, par value $0.00005 per share ("Common Stock"), of Brainstorm Cell Therapeutics Inc. (the "Registrant") reserved under the Registrant's 2014 Stock Incentive Plan and the 2014 Global Share Option Plan, each as amended through February 26, 2026 (as amended, collectively, the "2014 Plans"). This Registration Statement registers additional securities of the same class as other securities of the Registrant for which the registration statements filed on Form S-8 relating to the 2014 Plans ([File No. 333-198391](https://www.sec.gov/Archives/edgar/data/1137883/000114420414052667/v387660_s8.htm), [File No. 333-213714](https://www.sec.gov/Archives/edgar/data/1137883/000114420416124601/v448950_s8.htm), [File No. 333-228981](https://www.sec.gov/Archives/edgar/data/1137883/000114420418066053/tv508312_s8.htm), [File No. 333-261598](https://www.sec.gov/Archives/edgar/data/1137883/000110465921148601/tm2134979d1_s8.htm), and [File No. 333-288520)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925065799/tm2519000d1_s8.htm) of the Registrant are effective. The information contained in the Registrant's registration statements on Form S-8 relating to the 2014 Plans ([File No. 333-198391](https://www.sec.gov/Archives/edgar/data/1137883/000114420414052667/v387660_s8.htm), [File No. 333-213714](https://www.sec.gov/Archives/edgar/data/1137883/000114420416124601/v448950_s8.htm), [File No. 333-228981](https://www.sec.gov/Archives/edgar/data/1137883/000114420418066053/tv508312_s8.htm), [File No. 333-261598](https://www.sec.gov/Archives/edgar/data/1137883/000110465921148601/tm2134979d1_s8.htm), and [File No. 333-288520](https://www.sec.gov/Archives/edgar/data/1137883/000110465925065799/tm2519000d1_s8.htm)) is hereby incorporated by reference pursuant to General Instruction E of Form S-8, except with respect to Item 8. Exhibits thereof.

**Part II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8.** **Exhibits.**

The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement, and the contents of the Exhibit Index are incorporated herein by reference.

**EXHIBIT INDEX** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| <br>**Exhibit <br> Number** | <br>**Exhibit Description** | <br>**Filed<br> Herewith** | **Form** | **SEC File /<br> Registration<br> Number** | **Exhibit** | **Filing <br> Date** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [Certificate of Incorporation of Brainstorm Cell Therapeutics Inc.](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [333-61610](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [Appendix B](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [11/20/2006](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) | [Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated September 15, 2014.](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) | [000-54365](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) | [09/16/2014](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) |
| [4.3](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) | [Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated August 31, 2015.](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) |  | [8-K](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) | [001-366641](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) | [3.1](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) | [09/04/2015](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) | [Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 16, 2024.](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) | [001-366641](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) | [09/16/2024](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) |
| [4.5](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) | [Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 30, 2024.](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) | [001-366641](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) | [10/01/2024](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) |
| [4.6](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [ByLaws of Brainstorm Cell Therapeutics Inc.](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [333-61610](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [Appendix C](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [11/20/2006](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) |
| [4.7](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) | [Amendment No. 1 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of March 21, 2007.](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) | [333-61610](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) | [03/27/2007](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) |
| [4.8](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) | [Amendment No. 2 to the Bylaws of Brainstorm Cell Therapeutics Inc., dated as of April 20, 2025](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) | [333-61610](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) | [04/21/2025](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) |
| [5.1](tm2611422d1_ex5-1.htm) | [Opinion of Thompson Hine LLP](tm2611422d1_ex5-1.htm) | [X](tm2611422d1_ex5-1.htm) |  |  |  |  |
| [23.1](tm2611422d1_ex5-1.htm) | [Consent of Thompson Hine LLP (included in opinion of counsel filed as Exhibit 5.1)](tm2611422d1_ex5-1.htm) | [X](tm2611422d1_ex5-1.htm) |  |  |  |  |
| [23.2](tm2611422d1_ex23-2.htm) | [Consent of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network.](tm2611422d1_ex23-2.htm) | [X](tm2611422d1_ex23-2.htm) |  |  |  |  |
| [24](#a_001) | [Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)](#a_001) | [X](#a_001) |  |  |  |  |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| [99.1](http://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](http://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) |  | [8-K](http://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [000-54365](http://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [10.1](http://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [08/15/2014](http://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) |
| [99.2](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Amendment No. 1 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |  | [Definitive Schedule 14A](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [000-36641](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Appendix A](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [05/11/2016](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |
| [99.3](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [Amendment No. 2 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [10.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [11/30/2018](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) |
| [99.4](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Amendment No. 3 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Appendix A](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [10/01/2020](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |
| [99.5](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) | [Amendment No. 4 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) | [10.5](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) | [09/16/2024](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) |
| [99.6](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) | [Amendment No. 5 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) | [10.6](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) | [06/25/2025](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) |
| [99.7](http://www.sec.gov/Archives/edgar/data/0001137883/000110465926021613/tm267482d1_ex10-8.htm) | [Amendment No. 6 to Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan.](http://www.sec.gov/Archives/edgar/data/0001137883/000110465926021613/tm267482d1_ex10-8.htm) |  | [8-K](http://www.sec.gov/Archives/edgar/data/0001137883/000110465926021613/tm267482d1_ex10-8.htm) | [000-36641](http://www.sec.gov/Archives/edgar/data/0001137883/000110465926021613/tm267482d1_ex10-8.htm) | [10.8](http://www.sec.gov/Archives/edgar/data/0001137883/000110465926021613/tm267482d1_ex10-8.htm) | [02/27/2026](http://www.sec.gov/Archives/edgar/data/0001137883/000110465926021613/tm267482d1_ex10-8.htm) |
| [99.8](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [000-54365](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [10.2](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [08/15/2014](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) |
| [99.9](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Amendment No. 1 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Appendix B](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [05/11/2016](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |
| [99.10](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [Amendment No. 2 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [10.2](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [11/30/2018](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) |
| [99.11](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Amendment No. 3 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Appendix B](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [10/01/2020](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |
| [99.12](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [Amendment No. 4 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [10.10](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [09/16/2024](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) |
| [99.13](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) | [Amendment No. 5 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) | [10.12](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) | [06/25/2025](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) |
| [99.14](https://www.sec.gov/Archives/edgar/data/1137883/000110465926021613/tm267482d1_ex10-15.htm) | [Amendment No. 6 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan.](https://www.sec.gov/Archives/edgar/data/1137883/000110465926021613/tm267482d1_ex10-15.htm) |  | [8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001137883/000110465926021613/tm267482d1_8k.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465926021613/tm267482d1_ex10-15.htm) | [10.15](https://www.sec.gov/Archives/edgar/data/1137883/000110465926021613/tm267482d1_ex10-15.htm) | [02/27/2026](https://www.sec.gov/Archives/edgar/data/1137883/000110465926021613/tm267482d1_ex10-15.htm) |
| [107](tm2611422d1_ex-filingfees.htm) | [Filing Fee table](tm2611422d1_ex-filingfees.htm) | [X](tm2611422d1_ex-filingfees.htm) |  |  |  |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of New York, State of New York, on May 20, 2026.

---

| | |
|:---|:---|
| **BRAINSTORM CELL THERAPEUTICS INC.** | **BRAINSTORM CELL THERAPEUTICS INC.** |
| By: | /s/ Chaim Lebovits |
|  | **Chaim Lebovits** |
|  | **President and Chief Executive Officer** |

---

Each person whose signature appears below constitutes and appoints Chaim Lebovits, Uri Yablonka and Alla Patlis, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Chaim Lebovits<br> Chaim Lebovits | President and Chief Executive Officer<br> (Principal Executive Officer) | May 20, 2026 |
| /s/ *Alla Patlis*<br> *Alla Patlis* | Interim Chief Financial Officer<br> (Principal Financial and Accounting Officer) | May 20, 2026 |
| /s/ *Irit Arbel*<br> *Irit Arbel* | Director | May 20, 2026 |
| /s/ *Nir Naor*<br> *Nir Naor* | Director | May 20, 2026 |
| /s/ *Jacob Frenkel*<br> *Jacob Frenkel* | Director | May 20, 2026 |
| /s/ *Anthony Polverino*<br> *Anthony Polverino* | Director | May 20, 2026 |
| /s/ *Uri Yablonka*<br> *Uri Yablonka* | Director | May 20, 2026 |
| /s/ *Menghisteab Bairu*<br> *Menghisteab Bairu* | Director | May 20, 2026 |
| /s/ *Stacy Lindborg*<br> *Stacy Lindborg* | Director | May 20, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm2611422d1_ex5-1img001.jpg)

May 20, 2026

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas, 28<sup>th</sup> Floor

New York, NY 10019

Attention: Chief Executive Officer

Ladies and Gentlemen:

Brainstorm Cell Therapeutics Inc., a Delaware corporation (the "*Company*"), is filing with the U.S. Securities and Exchange Commission (the *"Commission*") a Registration Statement on Form S-8 (the "*Registration Statement*") for the registration, under the Securities Act of 1933, as amended (the "*Securities Act*"), of an additional 5,500,000 shares of common stock, $0.00005 par value, of the Company (the "*Common Stock*"), that are issuable at any time or from time to time under the Company's 2014 Stock Incentive Plan and 2014 Global Share Option Plan, each as amended (collectively, the "*Plans*").

In rendering the opinion below, we have examined the Plans, the Registration Statement, the certificate of incorporation of the Company, and the bylaws of the Company (each as amended and/or amended and restated as of the date hereof) and such other records, instruments, and documents as we have deemed advisable in order to render this opinion letter. In such examination, we have assumed (a) the genuineness of all signatures, (b) the legal capacity of all natural persons, (c) the authenticity of all documents, certificates, and instruments submitted to us as originals, (d) the conformity to original documents of all documents, certificates, and instruments submitted to us as certified, conformed, or photostatic copies, and (e) the authenticity of the originals of such latter documents. Our opinion set forth below is based on the text of the Plans as referenced in the Exhibits Index to the Registration Statement and is limited to the General Corporation Laws of the State of Delaware (the "*DGCL*") as currently in effect, and we express no opinion as to the effect on the matters covered by this letter of the laws of any other jurisdiction.

As a result of the foregoing, and subject to the further limitations, qualifications, and assumptions set forth herein, we are of the opinion that, when issued pursuant to and in accordance with the terms of the Plans, the Common Stock that is the subject of the Registration Statement will be validly issued, fully paid, and non-assessable.

In rendering the opinion above, we have assumed that (a) the Company will have sufficient authorized and unissued shares of Common Stock at the time of each issuance of any of the shares of Common Stock under the Plans; (b) the shares of Common Stock issued pursuant to the Plans will be evidenced by appropriate certificates, duly executed and delivered, or the Company's Board of Directors has adopted or will adopt a resolution providing that all of the shares of Common Stock shall be uncertificated in accordance with Section 158 of the DGCL prior to their issuance; (c) the issuance of each share of Common Stock issued pursuant to the Plans will be duly noted in the Company's stock ledger upon its issuance; (d) the Company will receive consideration for each share of Common Stock issued pursuant to the Plans at least equal to the par value of such share of Common Stock and in the amount required by the Plans (or the award agreement issued thereunder) and the Authorizing Resolutions (as defined below); (e) the resolutions authorizing the Company to issue the Common Stock pursuant to the Plans (the "*Authorizing Resolutions*") will be in full force and effect at all times at which the Common Stock is issued by the Company, and that the Company will take no action inconsistent with such Authorizing Resolutions; and (f) each award under the Plans will be approved by the Board of Directors of the Company or an authorized committee of the Board of Directors.

![](tm2611422d1_ex5-1img002.jpg)

May 20, 2026

This opinion letter speaks only as of the date hereof. We expressly disclaim any responsibility to advise you of any development or circumstance of any kind, including any change of law or fact that may occur after the date of this opinion letter that might affect the opinion expressed herein.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ Thompson Hine LLP |
| Thompson Hine LLP |

---

## Exhibit 23.2

**Exhibit 23.2**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in Registration Statement on Form S-8 of our report dated March 31, 2026, relating to the financial statements of Brainstorm Cell Therapeutics Inc. (the "Company") appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2025.

/s/ Brightman Almagor Zohar & Co.

**Brightman Almagor Zohar & Co.**

Certified Public Accountants

A Firm in the Deloitte Global Network

Tel Aviv, Israel

May 20, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **BRAINSTORM CELL THERAPEUTICS INC.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.00005 par value per share | 457(a) | 5500000 | $0.695 | $3822500.00 | 0.0001381 | $527.89 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $3822500.00  |  | $527.89  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $527.89  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> a) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, $0.00005 par value per share (the "Common Stock") of Brainstorm Cell Therapeutics Inc. (the "Registrant") that become issuable under the Registrant's 2014 Stock Incentive Plan and 2014 Global Share Option Plan, as amended (the "Plans"), by reason of any stock dividend, stock split, recapitalization or any other similar transactions. b) Represents an increase of 5,500,000 shares of Common Stock available for issuance under the Plans. c) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on $0.695, the average of the high and low sale prices of the Common Stock as reported on the OTCQB on May 17, 2026 (such date being within five business days of the date that this Registration Statement was filed with the Commission).

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---